Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio, Inc. (NASDAQ: GOSS) is a late-stage, clinical biopharmaceutical company centered on the development and commercialization of seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). The GOSS news feed on Stock Titan brings together company announcements, scientific updates, financial disclosures, and corporate developments that shape the investment and clinical narrative around its pulmonary hypertension programs.
News items for Gossamer Bio frequently cover progress in its registrational Phase 3 trials, including the PROSERA Study in PAH and the SERANATA Study in PH‑ILD. Investors and observers can follow updates on enrollment milestones, planned timelines for topline data, and key clinical endpoints such as six‑minute walk distance (6MWD), time to clinical worsening, and lung function measures. Scientific conference coverage, such as presentations at the European Respiratory Society (ERS) Congress, provides additional context on seralutinib’s mechanistic and translational data.
The GOSS news stream also reflects Gossamer Bio’s broader corporate and pipeline activities. This includes quarterly financial results and business updates, collaboration news with the Chiesi Group, stockholder meeting outcomes, and announcements related to its option agreement to acquire Respira Therapeutics and the investigational inhaled vardenafil candidate RT234. Regular disclosures of employment inducement stock option grants highlight hiring and equity compensation practices under Nasdaq Listing Rule 5635(c)(4).
By monitoring Gossamer Bio news on Stock Titan, readers can track how clinical data, regulatory milestones, scientific presentations, financial performance, and strategic transactions interact within the company’s focused pulmonary hypertension strategy. This page is intended as a central hub for GOSS-related headlines and press releases, helping users follow the evolution of its late-stage programs over time.
Gossamer Bio, a clinical-stage biopharmaceutical company (Nasdaq: GOSS), has announced a conference call and webcast on February 18, 2021, at 11:00 am ET. The event will discuss GB004, their oral HIF-1α stabilizer aimed at treating inflammatory bowel disease (IBD), specifically ulcerative colitis (UC). Esteemed experts in the field, including William Sandborn, Silvio Danese, and Cormac Taylor, will join Gossamer management for insights and a Q&A session. The webcast will be available on the company's website, and a replay will be accessible for 30 days.
Gossamer Bio, a clinical-stage biopharmaceutical company (Nasdaq: GOSS), announced a conference call and webcast on December 15, 2020, at 11:00 am ET to discuss GB002, an inhaled PDGFR inhibitor intended for treating pulmonary arterial hypertension (PAH). The event will feature insights from leading experts in PAH, Dr. Lewis Rubin and Dr. Vallerie McLaughlin. The session aims to cover GB002's development and its significance in addressing unmet therapeutic needs in PAH. The conference call can be accessed via the company's website.
Gossamer Bio has appointed Faheem Hasnain as Chief Executive Officer and President, succeeding Sheila Gujrathi, who served in the role since July 2018. Hasnain, a co-founder, previously led Receptos, Inc. before its acquisition by Celgene. In his new role, Hasnain aims to advance Gossamer's therapeutic pipeline in immunology, inflammation, and oncology. Dr. Gujrathi will remain as an advisor. The transition occurs as the company navigates the complexities of clinical-stage biopharmaceutical development, with a focus on unmet patient needs.
Gossamer Bio, Inc. (Nasdaq: GOSS) reported its Q3 2020 financial results, highlighting ongoing advancements in its clinical trials for GB002, GB004, and GB1275. GB002's Phase 2 trial for pulmonary arterial hypertension is set to enroll patients in Q4 2020, with topline data expected in H1 2022. GB004 is in a Phase 2 trial for inflammatory bowel disease, also targeting H1 2022 for topline data. Financially, Gossamer holds $555.4 million in liquid assets but reported a $57.8 million net loss for the quarter, influenced by increased interest expenses.
Gossamer Bio, Inc. (GOSS) will report its third quarter 2020 financial results on November 10, 2020. A live conference call will take place at 4:30 p.m. ET, allowing the management team to discuss the financial results and provide corporate updates. Interested parties can join the call using the domestic number (833) 646-0603 or international number (929) 517-9782. A subsequent audio webcast will be available for 30 days on their website.
Gossamer Bio (Nasdaq: GOSS) announced it will present data on GB1275 at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), held virtually from November 9-14, 2020. The presentation will include clinical and biomarker data from the ongoing Phase 1/2 trial, KEYNOTE-A36, focusing on advanced solid tumors. Two key posters will be presented by Dr. Johanna Bendell and Dr. Wells Messersmith, detailing the preliminary results and immune biomarker evaluations of GB1275, a CD11b modulator.
Gossamer Bio, Inc. (Nasdaq: GOSS) announced topline results from its Phase 2b LEDA trial for GB001 in patients with moderate-to-severe eosinophilic asthma and the Phase 2 TITAN trial for chronic rhinosinusitis. While the primary endpoint in the LEDA trial was not met, the results showed consistent numeric reductions in asthma worsening across all doses. Statistically significant improvements were noted in the secondary endpoint of time to first asthma worsening. The TITAN trial did not achieve its endpoints, leading to the decision not to pursue further development in that area.
Gossamer Bio (Nasdaq: GOSS) announced updates on its GB004 program targeting inflammatory bowel disease. At the UEGW Virtual Week 2020, data were presented from a Phase 1b study of GB004 in mild-to-moderate ulcerative colitis, showing safety and promising efficacy. Key outcomes included 17% mucosal healing and significant reduction in the inflammatory biomarker fecal calprotectin (38% reduction). The company is now screening patients for a global Phase 2 study (NCT04556383) with a primary endpoint of clinical remission at week 12, involving up to 195 subjects.
Gossamer Bio, Inc. (Nasdaq: GOSS) will present data on GB004 at the upcoming United European Gastroenterology Virtual Week 2020, from October 11-13. The oral presentation by Dr. William Sandborn will discuss clinical data from the completed Phase 1b trial for patients with active mild-to-moderate ulcerative colitis. Two sessions will showcase GB004's safety and protective effects on epithelial cells, signaling its potential in treating inflammatory bowel disease.